Search peptides, terms, sources/
Research source · 2018

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
Postmenopausal women with severe osteoporosis (1,360 women, 680 per group, in secondary VERO analyses)
Sample size
1360
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Comparator was risedronate only. The difference in non-vertebral fragility fractures was not statistically significant. Verified via Europe PMC on 14 November 2026.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.